How I investigate Clonal cytogenetic abnormalities of undetermined significance

• Published in: International journal of laboratory hematology 2018-08, Vol.40 (4), p.385-391
• Main Authors: Tang, G., Medeiros, L. J., Wang, S. A.
• Format: Article
• Language: English
• Subjects: clonal cytogenetic abnormalities; Dysplasia; Erythrocytes; Hematopoietic stem cells; Myelodysplastic syndrome; myelodysplastic syndromes; Stem cells; unknown significance
• ISSN: 1751-5521; 1751-553X
• DOI: 10.1111/ijlh.12826

Myelodysplastic syndromes are a group of hematopoietic stem cell diseases characterized by cytopenia(s), morphological dysplasia, and clonal hematopoiesis. In some patients, the cause of cytopenia(s) is uncertain, even after thorough clinical and laboratory evaluation. Evidence of clonal hematopoiesis has been used to support a diagnosis of myelodysplastic syndrome in this setting. In patients with cytopenia(s), the presence of clonal cytogenetic abnormalities, except for +8, del(20q) and −Y, can serve as presumptive evidence of myelodysplastic syndrome. Recent advances in next‐generation sequencing have detected myeloid neoplasm‐related mutations in patients who do not meet the diagnostic criteria for myelodysplastic syndrome. Various terms have been adopted to describe these cases, including clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS). Similarly, studies have shown that certain chromosomal abnormalities, including ones commonly detected in myelodysplastic syndrome, may not be associated necessarily with an underlying myelodysplastic syndrome. These clonal cytogenetic abnormalities of undetermined significance (CCAUS) are similar to CHIP and CCUS. Here, we review the features of CCAUS, distinguishing CCAUS from clonal cytogenetic abnormalities associated with myelodysplastic syndrome, and the potential impact of CCAUS on patient management.